Multiple Myeloma

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.

Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.

Samantha Shenoy, NP, MSN, indicated that neurological issues were not prevalent with talquetamab, despite occurrences with other bispecifics antibodies.

Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Panelists discuss how GPRC5D bispecific therapies have shown promising efficacy in real-world relapsed/refractory multiple myeloma patients.

Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.

The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.

Samantha Shenoy, NP, MSN, discussed common oral and dermatologic adverse effects associated with talquetamab in patients with myeloma.

Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.

A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.

Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.

Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.

James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.

Experts on multiple myeloma offer clinical insights on preparing patients who are going to receive GPRC5D therapy, highlighting step-up and treatment dosing for talquetamab.

Beth Faiman, CNP, PhD, outlines unique toxicities seen with other GPRC5D-targeted therapies in multiple myeloma.

Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.

Rafael Fonseca, MD, discusses the MonumenTAL-2 and MonumenTAL-3 clinical trials investigating talquetamab combination strategies in relapsed/refractory multiple myeloma.

Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.

A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.